Y Intercept Hong Kong Ltd Invests $1.94 Million in Sarepta Therapeutics, Inc. $SRPT

Y Intercept Hong Kong Ltd bought a new stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) in the 1st quarter, HoldingsChannel.com reports. The fund bought 88,944 shares of the biotechnology company’s stock, valued at approximately $1,935,000.

Several other large investors have also recently made changes to their positions in SRPT. Kestra Advisory Services LLC acquired a new stake in Sarepta Therapeutics during the fourth quarter valued at $25,000. iSAM Funds UK Ltd acquired a new stake in shares of Sarepta Therapeutics during the 3rd quarter valued at about $25,000. Ancora Advisors LLC increased its stake in shares of Sarepta Therapeutics by 200.0% in the 3rd quarter. Ancora Advisors LLC now owns 1,500 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 1,000 shares in the last quarter. Allworth Financial LP increased its position in shares of Sarepta Therapeutics by 2,098.8% in the third quarter. Allworth Financial LP now owns 1,803 shares of the biotechnology company’s stock valued at $35,000 after buying an additional 1,721 shares in the last quarter. Finally, Larson Financial Group LLC raised its stake in shares of Sarepta Therapeutics by 82.5% during the 4th quarter. Larson Financial Group LLC now owns 1,882 shares of the biotechnology company’s stock worth $41,000 after buying an additional 851 shares during the period. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Sarepta Therapeutics Stock Up 2.1%

SRPT stock opened at $20.21 on Thursday. The company has a current ratio of 4.63, a quick ratio of 2.62 and a debt-to-equity ratio of 0.56. The firm has a 50-day moving average of $17.80 and a two-hundred day moving average of $19.29. Sarepta Therapeutics, Inc. has a 12 month low of $10.41 and a 12 month high of $25.32. The company has a market cap of $2.13 billion, a price-to-earnings ratio of -21.05, a PEG ratio of 0.21 and a beta of 0.21.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its earnings results on Wednesday, May 6th. The biotechnology company reported $3.16 earnings per share for the quarter, topping the consensus estimate of $0.98 by $2.18. Sarepta Therapeutics had a positive return on equity of 7.56% and a negative net margin of 2.94%.The business had revenue of $730.80 million for the quarter, compared to analysts’ expectations of $474.15 million. During the same period in the previous year, the firm posted ($3.42) EPS. The business’s revenue for the quarter was down 1.9% compared to the same quarter last year. As a group, analysts forecast that Sarepta Therapeutics, Inc. will post 3.95 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on SRPT. Deutsche Bank Aktiengesellschaft lifted their price target on shares of Sarepta Therapeutics from $12.00 to $14.00 and gave the company a “sell” rating in a research note on Thursday, March 26th. Wall Street Zen raised shares of Sarepta Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, July 4th. Wedbush boosted their target price on shares of Sarepta Therapeutics from $29.00 to $35.00 and gave the stock an “outperform” rating in a research note on Thursday, March 26th. Royal Bank Of Canada upped their price target on shares of Sarepta Therapeutics from $18.00 to $19.00 and gave the stock a “sector perform” rating in a research report on Tuesday, April 7th. Finally, Needham & Company LLC reaffirmed an “underperform” rating on shares of Sarepta Therapeutics in a research note on Thursday, March 26th. Eight analysts have rated the stock with a Buy rating, ten have given a Hold rating and six have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Sarepta Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $24.81.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.